Please login to the form below

Not currently logged in
Email:
Password:

IVD

This page shows the latest IVD news and features for those working in and with pharma, biotech and healthcare.

Industry welcomes European diagnostics regulations

Industry welcomes European diagnostics regulations

scandal. The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) voiced qualified support for the new IVD regulations. ... However, the two trade bodies anticipate the added

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Brexit talks threaten supply of medical technologies Brexit talks threaten supply of medical technologies

    The timing is far from ideal. EU Member States have adopted new In Vitro Diagnostics (IVD) and Medical Devices (MD) Regulations. ... As this is a significant overhaul of the existing EU directives, authorities and companies have five years to adapt to

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Licence. Diagnostic products IVD. 75. Merck &Co / AstraZeneca. Licence. WEE1 kinase (MK-1775) for ovarian cancer.

  • Pharma deals during September 2013 Pharma deals during September 2013

    Strengthening another of its business units, Roche's diagnostic arm announced a licensing deal with Pacific Bioscience for human in vitro diagnostic (IVD) gene sequencing technology, paying $35m upfront and additional

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics